These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 36695327

  • 21. Clinical significance of UbA52 level in the urine of patients with type 2 diabetes mellitus and diabetic kidney disease.
    Xu X, Dong Y, Liu M, Li Y, Zhang Y.
    Nefrologia (Engl Ed); 2021; 41(5):548-555. PubMed ID: 36165137
    [Abstract] [Full Text] [Related]

  • 22. Urinary miR-3137 and miR-4270 as potential biomarkers for diabetic kidney disease.
    Li X, Xu R, Liu X, Xu L, Xue M, Cheng Y, Li T, Yu X, Wang Y, Li C, Sun B, Chen L.
    J Clin Lab Anal; 2020 Dec; 34(12):e23549. PubMed ID: 32869917
    [Abstract] [Full Text] [Related]

  • 23. Systemic immune-inflammation index is associated with diabetic kidney disease in Type 2 diabetes mellitus patients: Evidence from NHANES 2011-2018.
    Guo W, Song Y, Sun Y, Du H, Cai Y, You Q, Fu H, Shao L.
    Front Endocrinol (Lausanne); 2022 Dec; 13():1071465. PubMed ID: 36561561
    [Abstract] [Full Text] [Related]

  • 24. Clinical verification of a novel urinary microRNA panal: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis.
    Eissa S, Matboli M, Bekhet MM.
    Biomed Pharmacother; 2016 Oct; 83():92-99. PubMed ID: 27470555
    [Abstract] [Full Text] [Related]

  • 25. Expression levels of serum vasohibin-1 and other biomarkers in type 2 diabetes mellitus patients with different urinary albumin to creatinine ratios.
    Ren H, Shao Y, Ma X, Yang M, Liu Y, Wang Q.
    J Diabetes Complications; 2019 Jul; 33(7):477-484. PubMed ID: 31097304
    [Abstract] [Full Text] [Related]

  • 26. Performance of urinary neutrophil gelatinase-associated lipocalin, clusterin, and cystatin C in predicting diabetic kidney disease and diabetic microalbuminuria: a consecutive cohort study.
    Zeng XF, Lu DX, Li JM, Tan Y, Li Z, Zhou L, Xi ZQ, Zhang SM, Duan W.
    BMC Nephrol; 2017 Jul 12; 18(1):233. PubMed ID: 28701152
    [Abstract] [Full Text] [Related]

  • 27. Non-Proximal Renal Tubule-Derived Urinary Exosomal miR-200b as a Biomarker of Renal Fibrosis.
    Yu Y, Bai F, Qin N, Liu W, Sun Q, Zhou Y, Yang J.
    Nephron; 2018 Jul 12; 139(3):269-282. PubMed ID: 29539618
    [Abstract] [Full Text] [Related]

  • 28. Expression of apelin‑13 and its negative correlation with TGF‑β1 in patients with diabetic kidney disease.
    Wang Q, Liu X, Zhai A, Xu H, Ma S, Liu Y.
    Exp Ther Med; 2024 Mar 12; 27(3):110. PubMed ID: 38361517
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Implications of increased circulating macrophage inhibitory protein-5 in patients with type 2 diabetes mellitus.
    Zhao B, Zhang M, Xie J, Jiang T, Li J, Yang Z.
    Int Immunopharmacol; 2022 Aug 12; 109():108916. PubMed ID: 35679662
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Assessment of urinary podocalyxin as an alternative marker for urinary albumin creatinine ratio in early stage of diabetic kidney disease in older patients.
    Xie Y, Jin D, Qiu H, Lin L, Sun S, Li D, Sha F, Zhou W, Jia M.
    Nefrologia (Engl Ed); 2022 Aug 12; 42(6):664-670. PubMed ID: 36402681
    [Abstract] [Full Text] [Related]

  • 33. Urinary IgG, serum CX3CL1 and miRNA-152-3p: as predictors of nephropathy in Egyptian type 2 diabetic patients.
    Abdou AE, Anani HAA, Ibrahim HF, Ebrahem EE, Seliem N, Youssef EMI, Ghoraba NM, Hassan AS, Ramadan MAA, Mahmoud E, Issa S, Maghraby HM, Abdelrahman EK, Hassan HAM.
    Tissue Barriers; 2022 Jul 03; 10(3):1994823. PubMed ID: 34689723
    [Abstract] [Full Text] [Related]

  • 34. Increased urinary exosomal microRNAs in children with idiopathic nephrotic syndrome.
    Chen T, Wang C, Yu H, Ding M, Zhang C, Lu X, Zhang CY, Zhang C.
    EBioMedicine; 2019 Jan 03; 39():552-561. PubMed ID: 30467011
    [Abstract] [Full Text] [Related]

  • 35. Serum high mobility group box 1 as a potential biomarker for the progression of kidney disease in patients with type 2 diabetes.
    Liu T, Zhao H, Wang Y, Qu P, Wang Y, Wu X, Zhao T, Yang L, Mao H, Peng L, Zhan Y, Li P.
    Front Immunol; 2024 Jan 03; 15():1334109. PubMed ID: 38481996
    [Abstract] [Full Text] [Related]

  • 36. Diagnostic value of serum cathepsin S in type 2 diabetic kidney disease.
    Ren X, Wang W, Cao H, Shao F.
    Front Endocrinol (Lausanne); 2023 Jan 03; 14():1180338. PubMed ID: 37305031
    [Abstract] [Full Text] [Related]

  • 37. Exosomal miRNA-223-3p as potential biomarkers in patients with cerebral small vessel disease cognitive impairment.
    Zhao W, Sun W, Li S, Jiao Y, Wang Z, Wu T, Liu P, Tan L, Yin C.
    Ann Transl Med; 2021 Dec 03; 9(24):1781. PubMed ID: 35071475
    [Abstract] [Full Text] [Related]

  • 38. MicroRNAs and diabetic kidney disease: Systematic review and bioinformatic analysis.
    Assmann TS, Recamonde-Mendoza M, de Souza BM, Bauer AC, Crispim D.
    Mol Cell Endocrinol; 2018 Dec 05; 477():90-102. PubMed ID: 29902497
    [Abstract] [Full Text] [Related]

  • 39. Assessment of urinary NGAL for differential diagnosis and progression of diabetic kidney disease.
    Duan S, Chen J, Wu L, Nie G, Sun L, Zhang C, Huang Z, Xing C, Zhang B, Yuan Y.
    J Diabetes Complications; 2020 Oct 05; 34(10):107665. PubMed ID: 32653382
    [Abstract] [Full Text] [Related]

  • 40. The effects of Ophiocordyceps sinensis combined with ACEI/ARB on diabetic kidney disease: A systematic review and meta-analysis.
    Yan G, Chang T, Zhao Y, Yu M, Mi J, Wang G, Wang X, Liao X.
    Phytomedicine; 2023 Jan 05; 108():154531. PubMed ID: 36375237
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.